{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "About three-quarters of the patients who receive an expensive, invasive and risky laser treatment for the chest pains of heart disease do not meet the medical criteria for which it was approved, researchers reported yesterday. The Food and Drug Administration approved the treatment -- TMR, for transmyocardial revascularization -- only for patients with severe chest pains who could not have bypass surgery or angioplasty. But the researchers found that large numbers of surgeons are performing it while patients are having bypasses.", "headline": {"main": "Heart Laser Treatment Used Mostly on Patients Who Don't Meet the Federal Criteria"}, "abstract": null, "print_page": "28", "word_count": 1366, "_id": "4fd231b98eb7c8105d7c0e0a", "snippet": "About three-quarters of the patients who receive an expensive, invasive and risky laser treatment for the chest pains of heart disease do not meet the medical criteria for which it was approved, researchers reported yesterday.    The Food and Drug...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/06/us/heart-laser-treatment-used-mostly-patients-who-don-t-meet-federal-criteria.html", "multimedia": [], "subsection_name": null, "keywords": [], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gina", "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2003-11-06T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Drug companies have paid a total of $1.6 billion since 2001 to settle seven suits brought by whistle-blowers that accused them of marketing fraud and overbilling Medicare and Medicaid, according to a report released yesterday by an advocacy group. More fines are in the offing, the Washington-based group, Taxpayers Against Fraud, said in its report.", "headline": {"main": "Drug Makers Settled 7 Suits by Whistle-Blowers, Group Says"}, "abstract": "Taxpayers Against Fraud report shows drug companies AstraZeneca, Bayer, Dey, GlaxoSmithKline, Pfizer and TAP Pharmaceuticals have paid total of $1.6 billion since 2001 to settle seven suits brought by whistle-blowers that accused them of overbilling Medicare and Medicaid; says more fines are in offing; cases were brought under False Claims Act, Civil War-era status that allows individuals to sue on behalf of government when they believe contractor is defrauding government (M)", "print_page": "8", "word_count": 377, "_id": "4fd277688eb7c8105d838b4d", "snippet": "Drug companies have paid a total of $1.6 billion since 2001 to settle seven suits brought by whistle-blowers that accused them of marketing fraud and overbilling Medicare and Medicaid, according to a report released yesterday by an advocacy group.   ...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/06/business/drug-makers-settled-7-suits-by-whistle-blowers-group-says.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "TAXPAYERS AGAINST FRAUD"}, {"name": "organizations", "value": "DEY PHARMACEUTICALS"}, {"name": "organizations", "value": "TAP PHARMACEUTICALS"}, {"name": "organizations", "value": "GLAXOSMITHKLINE"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "organizations", "value": "ASTRAZENECA"}, {"name": "organizations", "value": "BAYER AG"}, {"name": "subject", "value": "FRAUDS AND SWINDLING"}, {"name": "subject", "value": "WHISTLE-BLOWERS"}, {"name": "subject", "value": "FINES (PENALTIES)"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICAID"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gardiner", "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2003-11-06T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "Series", "blog": [], "news_desk": "Foreign Desk", "lead_paragraph": "The first thing that struck Shen Yunxiang when he descended into the bowels of Hisun Pharmaceutical was the smell, or rather the lack of it. It was as if the sewage system had been scrubbed with ammonia, he said, leaving only a sickly sweet aroma strong enough to overpower the stench of human waste. In less than a minute, though, he realized that the company had exposed him to something far more noxious than feces. He had been sent, unwittingly, to release chemical runoff that Hisun had collected haphazardly beneath the factory, possibly to avoid paying fees to dispose of toxic waste.", "headline": {"main": "Foul Water and Air Part of Cost Of the Boom in China's Exports"}, "abstract": "Article in series World's Sweatshop, on hazards facing industrial workers in China, focuses on trade boom's environmental costs; at Hisun Pharmaceutical, one of China's leading exporters of pharmaceutical products, migrant workers have died after being exposed to toxic waste wearing no protective clothing; Hisun, in city of Taizhou, has undergone and passed seven inspections by Food and Drug Adm, intended to ensure that company meets American standards for product safety; FDA declines to answer questions about its inspections of Hisun; Eli Lilly & Co, which has alliance with Hisun to produce its drug capreomycin, says it has no knowledge of environmental or safety problems at Hisun; Hisun's case suggests that enormous human and environmental toll of China's rigid development is not just unintended side effect but also explicit choice of business executives and officials who tolerate deaths and degradation as inevitable price of progress; photos; map (L)", "print_page": "1", "word_count": 1862, "_id": "4fd249148eb7c8105d7e61e7", "snippet": "The first thing that struck Shen Yunxiang when he descended into the bowels of Hisun Pharmaceutical was the smell, or rather the lack of it. It was as if the sewage system had been scrubbed with ammonia, he said, leaving only a sickly sweet aroma...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/04/world/foul-water-and-air-part-of-cost-of-the-boom-in-china-s-exports.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "CHINA"}, {"name": "glocations", "value": "TAIZHOU (CHINA)"}, {"name": "organizations", "value": "HISUN PHARMACEUTICAL"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "LILLY, ELI, & CO"}, {"name": "organizations", "value": "CAPREOMYCIN"}, {"name": "subject", "value": "LABOR"}, {"name": "subject", "value": "INTERNATIONAL TRADE AND WORLD MARKET"}, {"name": "subject", "value": "SURVEYS AND SERIES"}, {"name": "subject", "value": "MIGRANT LABOR"}, {"name": "subject", "value": "HAZARDOUS AND TOXIC SUBSTANCES"}, {"name": "subject", "value": "ENVIRONMENT"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PROTECTIVE CLOTHING"}, {"name": "subject", "value": "INDUSTRIAL AND OCCUPATIONAL HAZARDS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Joseph", "lastname": "KAHN"}], "original": "By JOSEPH KAHN"}, "document_type": "article", "pub_date": "2003-11-04T00:00:00Z", "section_name": "World; Front Page; Health"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Scientists have created a highly lethal virus in an effort to develop stronger protections against supervirulent forms of smallpox that terrorists might turn on humans, researchers said yesterday. The genetic engineering involved a virus known as mousepox, which infects mice but is not known to hurt people. Into that virus the scientists spliced a single gene that made it superlethal, then tested it on mice treated with different combinations of a smallpox vaccine and drugs.", "headline": {"main": "Bioterror Researchers Build A More Lethal Mousepox"}, "abstract": "St Louis University researchers have created highly lethal form of mousepox for testing effectiveness of various combinations of smallpox vaccine and drugs on mice; project is funded by National Institute of Allergy and Infectious Diseases as part of effort to protect against bioterrorist attacks; critics argue such research could spur terrorists to create own deadly diseases; Prof Mark Buller, who leads project, holds it poses no human health risk; photo (M)", "print_page": "8", "word_count": 1003, "_id": "4fd24dc38eb7c8105d7eee09", "snippet": "Scientists have created a highly lethal virus in an effort to develop stronger protections against supervirulent forms of smallpox that terrorists might turn on humans, researchers said yesterday.     The genetic engineering involved a virus known as...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/01/us/bioterror-researchers-build-a-more-lethal-mousepox.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BULLER, MARK"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES"}, {"name": "organizations", "value": "ST LOUIS UNIVERSITY"}, {"name": "subject", "value": "BIOLOGICAL AND CHEMICAL WARFARE"}, {"name": "subject", "value": "VACCINATION AND IMMUNIZATION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "BUDGETS AND BUDGETING"}, {"name": "subject", "value": "TERRORISM"}, {"name": "subject", "value": "SMALLPOX"}, {"name": "subject", "value": "MICE"}], "byline": {"person": [{"firstname": "William", "middlename": "J.", "lastname": "BROAD", "rank": 1, "role": "reported", "organization": ""}], "original": "By WILLIAM J. BROAD"}, "document_type": "article", "pub_date": "2003-11-01T00:00:00Z", "section_name": "Health; U.S."}], "meta": {"hits": 4, "offset": 0, "time": 74}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}